Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MorphoSys Strengthens European Patent Position on Anti-CD19 Cancer Program MOR208

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
New patent has a scheduled expiry date in 2027.

MorphoSys AG has announced that the European Patent Office has granted a patent covering the Company's cancer compound MOR208.

The new patent (EP2383297) covers the antibody's protein and nucleic acid sequences as well as pharmaceutical compositions comprising the same.

The new patent has a scheduled expiry date in 2027, not including any potential patent office or regulatory extensions, and is licensed to MorphoSys AG from Xencor, Inc.

Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented: "MOR208 will be a key focus area for our development activities in the years to come and thus patent protection in the most relevant markets is of significant importance. Today's patent complements a new US patent covering the MOR208 antibody, which we announced a few weeks ago."

MOR208 is a humanized monoclonal antibody that targets the antigen CD19 for treatment of B cell malignancies and autoimmune diseases.

The antibody has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.

MOR208 has shown encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in a Phase 1/2a trial in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The study results showed an overall response rate of 29.6% (according to IWCLL 2008 criteria) based on the safety population of the trial (n=27).

MorphoSys is conducting Phase 2 clinical trials of MOR208 in patients with non-Hodgkin's lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys, MD Anderson Partner
MorphoSys AG and The University of Texas MD Anderson Cancer Center have announced a long-term strategic alliance for the discovery and development of novel therapeutic antibodies against cancer.
Wednesday, May 25, 2016
MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial
Phase 2 trial designed to support registration of anetumab ravtansine.
Wednesday, January 27, 2016
MorphoSys Presents Safety and Efficacy Data for MOR202 at ASH Meeting
MOR202 exhibits encouraging clinical activity and good safety profile with best-in-class infusion tolerability.
Tuesday, December 08, 2015
MorphoSys Publishes Update on MOR202 in Multiple Myeloma
First data from final 16 mg/kg dose escalation cohort and combination with immunomodulatory drugs show encouraging activity.
Thursday, September 24, 2015
MorphoSys Provides an Update on its Proprietary Development Portfolio
Lead cancer program MOR208 to be examined in numerous combination studies in hematological cancers.
Thursday, September 10, 2015
MorphoSys and Immatics Enter Strategic Alliance in Immuno-oncology
Collaboration aims to develop novel antibody-based therapies targeting tumor-associated peptides derived from intracellular proteins.
Tuesday, August 25, 2015
MorphoSys AG Reports Results for the First Six Months of 2015
Therapeutic pipeline exceeds 100 drug candidates in research & development.
Saturday, August 08, 2015
MorphoSys's Partner Heptares Initiates Proprietary Therapeutic Antibody Program
Successful discovery alliance combines two leading technologies.
Thursday, August 06, 2015
MorphoSys and G7 Therapeutics Sign Alliance
Collaboration broadens MorphoSys' capabilities to target novel antigen classes.
Thursday, August 06, 2015
MorphoSys Announces Clinical Milestone in Blood Disorders Program
Company has received milestone payment from Novartis.
Saturday, July 25, 2015
MorphoSys Presents Updated Phase 2 Clinical Results for MOR208
Matured data set shows six complete remissions with durable responses in diffuse large B-cell lymphoma and follicular lymphoma.
Thursday, June 04, 2015
MorphoSys Presents First Safety, Pharmacokinetic and Efficacy Data for MOR202
Clinical activity and long-lasting tumor control already observed at low doses.
Wednesday, June 03, 2015
MorphoSys to Present Data on Proprietary Programs at 20th Congress of EHA
Substantial data packages on lead compounds MOR202 and MOR208.
Tuesday, May 26, 2015
MorphoSys to Present Data on Proprietary Programs at ASCO Annual Meeting
Abstracts include first clinical data for MOR202.
Tuesday, May 26, 2015
MorphoSys AG Reports Results for the First Three Months of 2015
First quarter positively impacted by one-off effects relating to MOR202.
Tuesday, May 12, 2015
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Alzheimer's Genetics Point To New Research Direction
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Manufactured Stem Cells To Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Faster Detection of Pathogens in the Lungs
Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Anthrax Vaccine Protects Monkeys
Vaccination with the anthrax capsule—a naturally occurring component of the bacterium that causes the disease—completely protected monkeys from lethal anthrax infection, according to a recently published study.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!